EPCR Inhibitors
The class of EPCR inhibitors encompasses a diverse array of compounds targeting various cellular pathways to modulate the expression and function of Endothelial Protein C Receptor (EPCR). One notable group includes tyrosine kinase inhibitors such as R547 and Dasatinib, which act on focal adhesion kinase (FAK) and Src family kinases, respectively. Disruption of these kinases indirectly influences EPCR by interfering with integrin-mediated signaling and downstream processes associated with EPCR modulation. Additionally, small molecules like SB203580 and LY294002 play a crucial role as indirect EPCR inhibitors. SB203580, a p38 mitogen-activated protein kinase (MAPK) inhibitor, disrupts the p38 MAPK pathway, impacting cellular events linked to EPCR modulation. LY294002, a selective phosphoinositide 3-kinase (PI3K) inhibitor, alters downstream processes related to EPCR, illustrating the intricate interplay between PI3K signaling and EPCR regulation.
Furthermore, compounds such as BAY 11-7082 and Wortmannin provide indirect modulation of EPCR by targeting the NF-κB and PI3K-related kinase pathways, respectively. These inhibitors disrupt the inflammatory signaling cascades and cellular processes associated with EPCR, emphasizing the complexity of regulatory networks involved in EPCR expression. The class also includes inhibitors like SP600125, U0126, and BMS-345541, targeting JNK, MEK1/2, and IκB kinase (IKK), respectively. Through their actions on these key signaling components, these inhibitors exert downstream effects on pathways connected to EPCR, showcasing the diverse strategies employed by this class to influence EPCR expression and function. In summary, the class of EPCR inhibitors encompasses a range of chemical compounds that intricately modulate cellular pathways associated with EPCR. These inhibitors act through well-defined mechanisms, providing a nuanced understanding of how specific biochemical and cellular pathways influence the expression and activity of EPCR.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
R547 | 741713-40-6 | sc-364596 sc-364596A | 2 mg 5 mg | $375.00 $395.00 | ||
R547 is a potent and selective inhibitor of the focal adhesion kinase (FAK) signaling pathway. By targeting FAK, it disrupts integrin-mediated signaling, leading to downstream effects that indirectly modulate EPCR expression and function within cellular contexts. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a tyrosine kinase inhibitor, targets Src family kinases. Src kinases have been implicated in various cellular processes, including those related to EPCR signaling. Inhibition of Src kinases by Dasatinib can potentially influence downstream pathways, indirectly affecting the modulation of EPCR. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 mitogen-activated protein kinase (MAPK). By disrupting the p38 MAPK pathway, SB203580 can impact cellular processes associated with EPCR, providing an indirect means of modulating EPCR expression and activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a selective inhibitor of phosphoinositide 3-kinase (PI3K). PI3K is involved in various cellular signaling cascades, and its inhibition by LY294002 can influence downstream events that indirectly impact EPCR, altering its expression or functionality. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits the activation of NF-κB, a transcription factor involved in inflammatory responses. By modulating NF-κB activity, BAY 11-7082 can indirectly influence EPCR expression, as NF-κB is known to regulate genes involved in the inflammatory signaling cascades linked to EPCR modulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an irreversible inhibitor of PI3K-related kinases. Its impact on the PI3K pathway can have downstream effects on cellular processes influencing EPCR. The inhibition of PI3K-related kinases by Wortmannin provides an indirect mechanism for modulating EPCR expression or function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of c-Jun N-terminal kinase (JNK). By targeting JNK, SP600125 modulates the JNK signaling pathway, which can have downstream effects on cellular processes related to EPCR, serving as an indirect regulator of EPCR expression or function. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $312.00 | 1 | |
BMS-345541 selectively inhibits the IκB kinase (IKK) complex, a critical regulator of the NF-κB pathway. By targeting IKK, BMS-345541 can modulate NF-κB activity, indirectly impacting EPCR expression due to the regulatory role of NF-κB in the signaling cascades associated with EPCR modulation. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $67.00 $278.00 | 3 | |
LY303511 is a derivative of LY294002 and serves as a specific inhibitor of PI3K. Its impact on the PI3K pathway can influence downstream cellular processes, providing an indirect means of modulating EPCR expression or function by altering the PI3K-dependent signaling cascades linked to EPCR regulation. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
Tyrphostin B42 is a selective inhibitor of Janus kinase 2 (JAK2) and disrupts JAK/STAT signaling. The inhibition of JAK2 by Tyrphostin B42 can indirectly influence EPCR expression or function by modulating the JAK/STAT pathway, which is interconnected with signaling cascades related to EPCR modulation. | ||||||